Adagene vs Bolt Biotherapeutics
ADAG and BOLT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADAG and BOLT compare
Adagene grew revenue faster over the last twelve months (7333% versus 12.8% for Bolt Biotherapeutics).
Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −611% at Bolt Biotherapeutics.
Bolt Biotherapeutics scores higher on the StockData Score (11 against 5 for Adagene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADAG | BOLT |
|---|---|---|
| Size and price | ||
| Market cap | – | $11.7M |
| Share price | $1.71 | $6.08 |
| Change, 1 year | −3.4% | 29.6% |
| Change, 5 years | −82.5% | −96.5% |
| Beta (5Y) | 0.73 | 0.63 |
| Employees | 128 | 23 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.5× |
| P/B | – | 0.9× |
| Fair value | – | $8.70 |
| Margin of safety | – | 30.1% |
| Growth | ||
| Revenue growth (TTM) | 7333% (better) | 12.8% |
| Revenue growth, 5Y average | 61.4% | 102% (better) |
| Profitability | ||
| Operating margin | −279% (better) | −655% |
| Net margin | −230% (better) | −611% |
| FCF margin | −204% | – |
| Return on equity | −27.7% (better) | −112% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Interest coverage | −46.3× | – |
| Current ratio | 5.02 (better) | 2.61 |
| Altman Z-score | – | −18.28 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.26% |
| Shareholder yield | – | −0.26% |
| Ownership | ||
| Held by institutions | 32.5% | 31.0% |
| Held by insiders | 16.8% | 12.2% |
| Insider net buying, 12 months | $162K | $196K (better) |
| Short interest, % of float | – | 2.8% |
Go deeper
- ADAG stock overview
- ADAG income statement
- ADAG valuation and score
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.